Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues

Conclusions
Baseline anti-HBc titre is a useful predictor of Peg-IFN and NUC therapy efficacy in HBeAg-positive CHB patients, which could be used for optimising the antiviral therapy of CHB.

Source: Gut - January 6, 2016 Category: Gastroenterology Authors: Fan, R., Sun, J., Yuan, Q., Xie, Q., Bai, X., Ning, Q., Cheng, J., Yu, Y., Niu, J., Shi, G., Wang, H., Tan, D., Wan, M., Chen, S., Xu, M., Chen, X., Tang, H., Sheng, J., Lu, F., Jia, J., Zhuang, H., Xia, N., Hou, J., Chronic Hepatitis B Study Consortium, Tags: Hepatitis B, Open access Hepatology Source Type: research